AbCellera Biologics (ABCL) EBT (2020 - 2023)
AbCellera Biologics (ABCL) has disclosed EBT for 4 consecutive years, with -$48.6 million as the latest value for Q4 2023.
- For the quarter ending Q4 2023, EBT fell 54.72% year-over-year to -$48.6 million, compared with a TTM value of -$174.0 million through Dec 2023, down 172.79%, and an annual FY2024 reading of -$200.4 million, down 15.15% over the prior year.
- EBT was -$48.6 million for Q4 2023 at AbCellera Biologics, down from -$39.3 million in the prior quarter.
- Across five years, EBT topped out at $230.8 million in Q1 2022 and bottomed at -$48.6 million in Q4 2023.
- Average EBT over 4 years is $28.0 million, with a median of -$2.4 million recorded in 2020.
- Peak annual rise in EBT hit 7815.58% in 2021, while the deepest fall reached 827.4% in 2021.
- Year by year, EBT stood at $161.2 million in 2020, then plummeted by 47.44% to $84.7 million in 2021, then plummeted by 137.08% to -$31.4 million in 2022, then tumbled by 54.72% to -$48.6 million in 2023.
- Business Quant data shows EBT for ABCL at -$48.6 million in Q4 2023, -$39.3 million in Q3 2023, and -$38.0 million in Q2 2023.